Measure Information Form Collected For: CMS Voluntary Only The Joint Commission - Retired

Size: px
Start display at page:

Download "Measure Information Form Collected For: CMS Voluntary Only The Joint Commission - Retired"

Transcription

1 Measure Information Form Collected For: CMS Voluntary Only The Joint Commission - Retired Last Updated: Version 4.3a Measure Set: Pneumonia (PN) Set Measure I #: Performance Measure Name: lood Cultures Performed in the Emergency epartment Prior to Initial Antibiotic Received in Hospital escription: Pneumonia patients whose initial emergency room blood culture specimen was collected prior to first hospital dose of antibiotics. This measure focuses on the treatment provided to Emergency epartment patients prior to admission orders. Rationale: Although recommendations for blood cultures are controversial due to the overall low yield, they can have a significant impact on the care of an individual patient and are important for epidemiologic reasons, such as antibiotic susceptibility patterns used to develop treatment guidelines. The Joint ISA/ATS Guidelines on the Management of Community-Acquired Pneumonia (CAP) in Adults recommend that certain patients with pneumonia should be investigated for specific pathogens that would significantly alter decisions regarding empirical therapy, when the presence of these pathogens is suspected (Mandell, 2007). The guidelines recommend that pretreatment blood samples for culture should be obtained from hospitalized pneumonia patients who are admitted to the Intensive Care Unit, have cavitary infiltrates, leukopenia, chronic severe liver disease, asplenia, plural effusion, have a positive pneumococcal urinary antigen test (UAT), and have active alcohol abuse (Mandell, 2007). Pretreatment cultures are recommended because the yield of clinically useful information is greater if the culture is collected before antibiotics are administered. In a large retrospective study of blood cultures in pneumonia patients, Metersky et al demonstrated that when patients are selected appropriately, for example, those who are sicker or have co-morbid conditions like liver disease, etc., the yield of blood culture pathogens was doubled for each risk factor. The study also demonstrated that doing cultures after antibiotics were given decreased yield by 50%. This measure focuses on treatment provided in the Emergency epartment where the largest number and variety of pneumonia patients receive treatment prior to admission orders. A review of performance measure data from the pneumonia national hospital quality measures over the past few years indicates that 68 to 70% of patients admitted to the hospital for pneumonia receive care and services in the E prior to admission. Emergency epartments serve patients with a variety of co-morbidities such as those indicated above and varying levels of severity related to their clinical condition. The E also serves as a triage point for the next level of care; intensive care, or general unit. In concordance with the guideline recommendations, the performance measure does not -1

2 require blood cultures for all E patients, but if a culture is done, it must be done prior to administration of the first dose of antibiotics received in the hospital in order to meet the intent of this measure. Type of Measure: Process Improvement Noted As: An increase in the rate Numerator Statement: Number of pneumonia patients whose initial emergency room blood culture was performed prior to the administration of the first hospital dose of antibiotics. Included Populations: Not Applicable Excluded Populations: None ata Elements: Antibiotic Administration ate Antibiotic Administration Time Antibiotic Name Arrival ate Arrival Time lood Culture Collected Initial lood Culture Collection ate Initial lood Culture Collection Time enominator Statement: Pneumonia patients 18 years of age and older who have an initial blood culture collected as an emergency department patient. Included Populations: ischarges with: An IC-9-CM Principal iagnosis Code of pneumonia as defined in Appendix A, Table 3.1 OR IC-9-CM Principal iagnosis Code of septicemia or respiratory failure (acute or chronic) as defined in Appendix A, Tables 3.2 or 3.3 AN An IC-9-CM Other iagnosis Code of pneumonia (Appendix A, Table 3.1) Excluded Populations: Patients less than 18 years of age Patients who have a Length of Stay greater than 120 days Patients with Cystic Fibrosis (Appendix A, Table 3.4) Patients who had no chest x-ray or CT scan that indicated abnormal findings within 24 hours prior to hospital arrival or anytime during this hospitalization Patients with Comfort Measures Only documented day of or day after arrival -2

3 Patients enrolled in clinical trials Patients not admitted through the E Patients who had no diagnosis of pneumonia either as the E final diagnosis/impression or direct admission diagnosis/impression Patients who only received antibiotics prior to hospital arrival Patients who do not receive any antibiotics within 24 hours after arrival Patients who do not receive a blood culture Patients who do not have a blood culture collected in the E prior to admission order Patients who have a blood culture collected within 24 hours prior to hospital arrival Patients discharged to another hospital on day of or day after arrival Patients who left against medical advice on day of or day after arrival Patients who expired on day of or day after arrival ata Elements: Admission ate Antibiotic Received irthdate Chest -ray Clinical Trial Comfort Measures Only ischarge ate ischarge isposition IC-9-CM Other iagnosis Codes IC-9-CM Principal iagnosis Code Pneumonia iagnosis: E/irect Admit Risk Adjustment: No ata Collection Approach: Retrospective data sources for required data elements include administrative data and medical record documents. Some hospitals may prefer to gather data concurrently by identifying patients in the population of interest. This approach provides opportunities for improvement at the point of care/service. However, complete documentation includes the principal or other IC-9-CM diagnosis and procedure codes, which require retrospective data entry. ata Accuracy: Variation may exist in the assignment of IC-9-CM codes; therefore, coding practices may require evaluation to ensure consistency. To be part of the measure population, a patient must have received an antibiotic either during the hospitalization or within 24 hours prior to hospital arrival plus during the hospitalization. Measure specifications do not require documentation of the exact date and time of the antibiotic taken prior to hospitalization. To be part of the measure population, a patient must be an Emergency epartment patient and have a blood culture collected prior to an admission order. -3

4 Measure Analysis Suggestions: None Sampling: Yes, please refer to the measure set specific sampling requirements and for additional information see the Population and Sampling Specifications section. ata Reported As: Aggregate rate generated from count data reported as a proportion Selected References: Heffelfinger J, owell SF, Jorgensen JH, Klugman KP, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the rug-resistant Streptococcus Pneumoniae Therapeutic Working Group. Archives of Internal Medicine. 2000, 160: King M, Whitney CG, Parekh F, Farley MM. Recurrent invasive pneumococcal disease: a population-based assessment. Clin Infect is 2003; 37: Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious isease Society and the Canadian Thoracic Society. Clin Infect is 2000;31: Mandell LA, Wunderink RG, Anzueta A, artlett JG, Infectious iseases Society of America; American Thoracic Society. Infectious iseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect is March 1;44 Suppl 2:S Metersky ML, Ma A, ratzler W, et al. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med 2004; 169: van der Eerden MM, Vlaspolder F, de Graaf CS, Groot T, ronsveld W, Jansen HM. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005; 60:

5 : lood Cultures Performed in the Emergency epartment Prior to Initial Antibiotic Received in Hospital Numerator: Number of pneumonia patients whose initial E blood culture was performed prior to the administration of the first hospital dose of antibiotics. enominator: Pneumonia patients 18 years of age and older who have initial blood culture collected in the E. START Run cases that are included in the PN Initial Patient Population and pass the edits defined in the Transmission ata Processing Flow: Clinical through this measure. Variable Key: Antibiotic Timing lood Culture Timing lood Culture Collection ay uration of Stay Initial Antibiotic ate Initial Antibiotic Time Chest -Ray = 2, 3 = 1 Comfort Measures Only = 1 = 2, 3, 4 Clinical Trial = Y = N H -5

6 H Pneumonia iagnosis: E/ irect Admit = 2 = 1, 3 Pneumonia iagnosis: E/ irect Admit = 3 = 1 Antibiotic Received = 1 or 4 = 2 or 3 lood Culture Collected = 2,3,4 = 1 Arrival ate = UT Non-UT Value uration of Stay = ischarge ate Arrival ate (in days) uration of Stay 1 ischarge isposition = 4, 6, 7 >1 = 1, 2, 3, 5, 8 Arrival Time =UT Non-UT Value I -6

7 I Antibiotic Grid Not Populated Antibiotic Name Note: The front-end edits reject cases containing invalid data and/or an incomplete Antibiotic Grid. A complete Antibiotic Grid requires all data elements in the row to contain either a valid value and/or UT. On table 2.1 Note: Proceed only with Antibiotics that have an associated non-ut Antibiotic Administration ate Antibiotic Administration ate =UT for all antibiotic doses Non-UT Value for at least one antibiotic dose Initial Antibiotic ate = The Antibiotic Administration ate that corresponds to the initial antibiotic dose. Note: The initial antibiotic dose is the earliest antibiotic dose administered that is on Table If there is more than one antibiotic on the earliest date, select the one having the earliest non-ut Antibiotic Administration Time. - If there is only one antibiotic on the earliest date retain that earliest antibiotic as the Initial Antibiotic ose. Initial lood Culture Collection ate =UT Non-UT Value lood Culture Collection ay (in days) = Initial Antibiotic ate minus Initial lood Culture Collection ate < 0 days lood Culture Collection ay > 0 days E = 0 day Antibiotic Administration Time =UT for the antibiotic considered the Initial Antibiotic ate Non-UT time for the antibiotic considered the Initial Antibiotic ate J -7

8 J Initial Antibiotic Time = The Antibiotic Administration Time that corresponds to the initial antibiotic dose. Initial lood Culture Collection Time =UT Non-UT Value Antibiotic Timing = Initial Antibiotic ate and Initial Antibiotic Time minus Arrival ate and Arrival Time (in minutes) Will e Rejected Case < 0 minutes Antibiotic Timing 0 minutes Z lood Culture Timing = Initial Antibiotic ate and Initial Antibiotic Time minus Initial lood Culture Collection ate and Initial lood Culture Collection Time (in minutes) lood Culture Timing In Measure < 0 minutes Population Not In Measure Population E 0 minutes E In Numerator Population Z STOP -8

9 Pneumonia (PN) - 3b: lood Cultures Performed in the Emergency epartment Prior to Initial Antibiotic Received in Hospital Numerator: enominator: Variable Key: Number of pneumonia patients whose initial Emergency epartment (E) blood culture was performed prior to the administration of the first hospital dose of antibiotics. Pneumonia patients 18 years of age and older who have initial blood culture collected in the E. Antibiotic Timing, lood Culture Timing, lood Culture Collection ay, uration of Stay, Initial Antibiotic ate, and Initial Antibiotic Time. 1. Start Run cases that are included in the Pneumonia (PN) Initial Patient Population and pass the edits defined in the Transmission ata Processing Flow: Clinical through this measure. 2. Check Chest -Ray a. If Chest -Ray is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop b. If Chest -Ray equals 2 or 3, the case will proceed to a Measure Category Assignment of and will not be in the Measure Population. Stop c. If Chest -Ray equals 1, continue processing and proceed to Comfort Measures Only. 3. Check Comfort Measures Only a. If Comfort Measures Only is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop b. If Comfort Measures Only equals 1, the case will proceed to a Measure Category Assignment of and will not be in the Measure Population. Stop c. If Comfort Measures Only equals 2, 3, or 4, continue processing and proceed to Clinical Trial. 4. Check Clinical Trial a. If Clinical Trial is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop b. If Clinical Trial equals Yes, the case will proceed to a Measure Category Assignment of and will not be in the Measure Population. Stop c. If Clinical Trial equals No, continue processing and proceed to Pneumonia iagnosis: E/irect Admit. -9

10 5. Check Pneumonia iagnosis: E/irect Admit a. If Pneumonia iagnosis: E/irect Admit is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop b. If Pneumonia iagnosis: E/irect Admit equals 2, the case will proceed to a Measure Category Assignment of and will not be in the Measure Population. Stop c. If Pneumonia iagnosis: E/irect Admit equals 3, the case will proceed to a Measure Category Assignment of and will be in the Measure Population. Stop d. If Pneumonia iagnosis: E/irect Admit equals 1, continue processing and proceed to Antibiotic Received. 6. Check Antibiotic Received a. If Antibiotic Received is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop b. If Antibiotic Received equals 1 or 4, the case will proceed to a Measure Category Assignment of and will not be in the Measure Population. Stop c. If Antibiotic Received equals 2 or 3, continue processing and proceed to lood Culture Collected. 7. Check lood Culture Collected a. If lood Culture Collected is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop b. If lood Culture Collected equals 2, 3, or 4, the case will proceed to a Measure Category Assignment of and will not be in the Measure Population. Stop c. If lood Culture Collected equals 1, continue processing and proceed to Arrival ate. 8. Check Arrival ate a. If the Arrival ate is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop b. If the Arrival ate equals Unable to etermine, the case will proceed to a Measure Category Assignment of and will be in the Measure Population. Stop c. If the Arrival ate equals a Non Unable to etermine Value, continue processing and proceed to the uration of Stay calculation. 9. Calculate uration of Stay. uration of Stay, in days, is equal to the ischarge ate minus the Arrival ate. 10. Check uration of Stay -10

11 a. If the uration of Stay is greater than 1, continue processing and proceed to step 12 to check Arrival Time. o not check ischarge isposition. b. If the uration of Stay is less than or equal to 1, continue processing and proceed to ischarge isposition. 11. Check ischarge isposition only if uration of Stay was less than or equal to 1 a. If the ischarge isposition equals 4, 6, or 7 the case will proceed to a Measure Category Assignment of and will not be in the Measure Population. Stop b. If ischarge isposition equals 1, 2, 3, 5, or 8, continue processing and proceed to Arrival Time. 12. Check Arrival Time a. If the Arrival Time is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop b. If the Arrival Time equals Unable to etermine, the case will proceed to a Measure Category Assignment of and will be in the Measure Population. Stop c. If the Arrival Time equals a Non Unable to etermine Value, continue processing and proceed to Antibiotic Name. 13. Check Antibiotic Name a. If the Antibiotic Name is on Table 2.1, continue processing and proceed to Antibiotic Administration ate. b. If the Antibiotic Grid is not populated, the case will proceed to a Measure Category Assignment of and will be rejected. Stop Note: The front-end edits reject cases containing invalid data and/or an incomplete Antibiotic Grid. A complete Antibiotic Grid requires all data elements in the row to contain either a valid value and/or Unable to etermine. 14. Check Antibiotic Administration ate a. If the Antibiotic Administration ate equals Unable to etermine for all antibiotic doses, the case will proceed to a Measure Category Assignment of and will be in the Measure Population. Stop b. If the Antibiotic Administration ate equals a Non Unable to etermine Value for at least one antibiotic dose, continue processing and proceed to the Initial Antibiotic ate determination. Note: Proceed only with Antibiotics that have an associated Non Unable to etermine Antibiotic Administration ate. 15. etermine the Initial Antibiotic ate. The Initial Antibiotic ate equals the Antibiotic Administration ate that corresponds to the initial antibiotic dose. -11

12 Note: The initial antibiotic dose is the earliest antibiotic dose administered that is on Table 2.1. If there is more than one antibiotic on the earliest date, select the one having the earliest non Unable to etermine Antibiotic Administration Time. If there is only one antibiotic on the earliest date, retain that earliest antibiotic as the Initial Antibiotic ose. 16. Check Initial lood Culture Collection ate a. If the Initial lood Culture Collection ate is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop b. If the Initial lood Culture Collection ate equals Unable to etermine, the case will proceed to a Measure Category Assignment of and will be in the Measure Population. Stop c. If the Initial lood Culture Collection ate equals a Non Unable to etermine Value, continue processing and proceed to the lood Culture Collection ay calculation. 17. Calculate lood Culture Collection ay. lood Culture Collection ay, in days, is equal to the Initial Antibiotic ate minus the Initial lood Culture Collection ate. 18. Check lood Culture Collection ay a. If the lood Culture Collection ay is less than zero days, the case will proceed to a Measure Category Assignment of and will be in the Measure Population. Stop b. If the lood Culture Collection ay is greater than zero days, the case will proceed to a Measure Category Assignment of E and will be in the Numerator Population. Stop c. If the lood Culture Collection ay is equal to zero days, continue processing and proceed to Antibiotic Administration Time. 19. Check Antibiotic Administration Time a. If the Antibiotic Administration Time is equal to Unable to etermine for the antibiotic that is considered the Initial Antibiotic ate, the case will proceed to a Measure Category Assignment of and will be in the Measure Population. b. If the Antibiotic Administration Time is a Non Unable to etermine time for the antibiotic that is considered the Initial Antibiotic ate, continue processing and proceed to determine the Initial Antibiotic Time. 20. etermine the Initial Antibiotic Time. The Initial Antibiotic Time is equal to the Antibiotic Administration Time that corresponds to the Initial Antibiotic ose. 21. Check Initial lood Culture Collection Time -12

13 a. If the Initial lood Culture Collection Time is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop b. If the Initial lood Culture Collection Time equals Unable to etermine, the case will proceed to a Measure Category Assignment of and will be in the Measure Population. Stop c. If the Initial lood Culture Collection Time equals a Non Unable to etermine Value, continue processing and proceed to the Antibiotic Timing calculation. 22. Calculate Antibiotic Timing. Antibiotic Timing, in minutes, is equal to the Initial Antibiotic ate and Initial Antibiotic Time minus the Arrival ate and Arrival Time. 23. Check Antibiotic Timing a. If the Antibiotic Timing is less than zero minutes, the case will proceed to a Measure Category Assignment of and will be rejected. Stop b. If the Antibiotic Timing is greater than or equal to zero minutes, continue processing and proceed to the lood Culture Timing calculation. 24. Calculate lood Culture Timing. lood Culture Timing, in minutes, is equal to the Initial Antibiotic ate and Initial Antibiotic Time minus the Initial lood Culture Collection ate and initial lood Culture Collection Time. 25. Check lood Culture Timing a. If the lood Culture Timing is less than zero minutes, the case will proceed to a Measure Category Assignment of and will be in the Measure Population. Stop b. If the lood Culture Timing is greater than or equal to zero minutes, the case will proceed to a Measure Category Assignment of E and will be in the Numerator Population. Stop -13

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Last Updated: Version 3.2a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Organization Set Measure ID#

More information

Measure Information Form

Measure Information Form Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form

More information

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Voluntary Only

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Voluntary Only Last Updated: Version 4.4a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Collected For: CMS Voluntary

More information

Measure Information Form

Measure Information Form Release Notes: Measure Information Form Version 2.0 Measure Information Form Measure Set: Pneumonia (PN) Set Measure ID #: Organization Set Measure ID# Time Intervals JCHO 0-8 hours CMS/JCHO 0-4 hours

More information

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Voluntary Only

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Voluntary Only Last Updated: Version 4.4a NQF-ENORSE VOLUNTARY CONSENSUS STANARS FOR HOSPITAL CARE Measure Information Form Collected For: CMS Voluntary Only Measure Set: Surgical Care Improvement Project (SCIP) Set

More information

Measure Information Form

Measure Information Form Release Notes: Measure Information Form Version 2.4 **NQF-NORS VOLUNTARY CONSNSUS STANARS FOR HOSPITAL CAR** Measure Information Form Measure Set: Surgical Care Improvement Project (SCIP) Set Measure I

More information

National Hospital Quality Measures Measure Definitions

National Hospital Quality Measures Measure Definitions National Hospital Quality Measures Measure efinitions Excerpts from the Specifications Manual for National Hospital Quality Measures for Surgical Care Improvement Project Measure Set Applicable to Cases

More information

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Voluntary Only

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Voluntary Only Last Updated: Version 4.4a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Infmation Fm Collected F: CMS Voluntary Only Measure Set: Surgical Care Improvement Project (SCIP) Set Measure

More information

ESISTONO LE HCAP? Francesco Blasi. Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano

ESISTONO LE HCAP? Francesco Blasi. Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano ESISTONO LE HCAP? Francesco Blasi Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano Community-acquired pneumonia (CAP): Management issues

More information

Pneumococcal urinary antigen test use in diagnosis and treatment of pneumonia in seven Utah hospitals

Pneumococcal urinary antigen test use in diagnosis and treatment of pneumonia in seven Utah hospitals ORIGINAL ARTICLE PNEUMONIA Pneumococcal urinary antigen test use in diagnosis and treatment of pneumonia in seven Utah hospitals Devin M. West 1, Lindsay M. McCauley 2,3, Jeffrey S. Sorensen 2, Al R. Jephson

More information

Antibiotics Use And Concordance To Guidelines For Patients Hospitalized With Community Acquired Pneumonia (CAP)

Antibiotics Use And Concordance To Guidelines For Patients Hospitalized With Community Acquired Pneumonia (CAP) Antibiotics Use And Concordance To Guidelines For Patients Hospitalized With Community Acquired Pneumonia (CAP) SF Teoh 1, Samsinah Hussain 1, CK Liam 2 1 Departments of Pharmacy, Faculty of Medicine,

More information

IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP)

IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,

More information

Control emergence of drug-resistant. Reduce costs

Control emergence of drug-resistant. Reduce costs ...PRESENTATIONS... Guidelines for the Management of Community-Acquired Pneumonia Richard E. Chaisson, MD Presentation Summary Guidelines for the treatment of community-acquired pneumonia (CAP) have been

More information

IDSA GUIDELINES COMMUNITY ACQUIRED PNEUMONIA

IDSA GUIDELINES COMMUNITY ACQUIRED PNEUMONIA page 1 / 5 page 2 / 5 idsa guidelines community acquired pdf IDSA/ATS Guidelines for CAP in Adults CID 2007:44 (Suppl 2) S29 such as blood and sputum cultures. Conversely, these cultures may have a major

More information

Bai-Yi Chen MD. FCCP

Bai-Yi Chen MD. FCCP Treatment strategies for hospitalized versus nonhospitalized CAP patients: Asian perspective Bai-Yi Chen MD. FCCP Professor of Medicine Division of Infectious Disease, Infection Control Team The First

More information

The Three R s Rethink..Reduce..Rocephin

The Three R s Rethink..Reduce..Rocephin The Three R s Rethink..Reduce..Rocephin By: Alisa Cuff RN,BN,CIC and John Bautista B.Sc. (Chem), B.Sc.Pharm, M.Sc.Pharm IPAC National Conference 2017 Newfoundland and Labrador Regional Health Authorities

More information

GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS

GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes

More information

UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients

UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management

More information

Antibiotic Therapy and 48-Hour Mortality for Patients with Pneumonia

Antibiotic Therapy and 48-Hour Mortality for Patients with Pneumonia The American Journal of Medicine (2006) 119, 859-864 CLINICAL RESEARCH STUDY AJM Theme Issue: Pulmonology/Allergy Antibiotic Therapy and 48-Hour Mortality for Patients with Pneumonia Eric M. Mortensen,

More information

Compliance with antibiotic treatment guidelines in managed care patients with communityacquired pneumonia in ambulatory settings

Compliance with antibiotic treatment guidelines in managed care patients with communityacquired pneumonia in ambulatory settings Compliance with antibiotic treatment guidelines in managed care patients with communityacquired pneumonia in ambulatory settings Jasmanda H. Wu, Ph.D., 1 David H. Howard, Ph.D., 2 John E. McGowan, Jr.,

More information

Survey of Wisconsin Primary Care Clinicians

Survey of Wisconsin Primary Care Clinicians ... for our health Clinical Approach to Nonresponsive Pneumonia: A Survey of Wisconsin Primary Care Clinicians Hannah A. Louks, 1,3 Jared M. Fixmer, MD 2, and Dennis J. Baumgardner, MD 1,2,3 1 Wisconsin

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Nuzyra) Reference Number: CP.PMN.## Effective Date: 11.20.18 Last Review Date: 02.19 Line of Business: Commercial, TBD HIM*, Medicaid Coding Implications Revision Log See Important Reminder

More information

Measure Information Form

Measure Information Form Release Notes: Measure Information Form Version 2.0 **NQF-NDORSD VOLUNTRY CONSNSUS STNDRDS FOR HOSPITL CR** Measure Information Form Measure Set: Surgical Care Improvement Project (SCIP) Set Measure ID

More information

Evaluating the Role of MRSA Nasal Swabs

Evaluating the Role of MRSA Nasal Swabs Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization

More information

Welcome! 10/26/2015 1

Welcome! 10/26/2015 1 Welcome! Audio for this event is available via ReadyTalk Internet Streaming. No telephone line is required. Computer speakers or headphones are necessary to listen to streaming audio. Limited dial-in lines

More information

Measure Information Form

Measure Information Form Release Notes: Measure Information Form Version 2.0 **NQF-NDORSD VOUNTRY CONSNSUS STNDRDS FOR HOSPIT CR** Measure Information Form Measure Set: Surgical Care Improvement Project (SCIP) Set Measure ID #:

More information

Community Acquired Pneumonia: An Update on Guidelines

Community Acquired Pneumonia: An Update on Guidelines Community Acquired Pneumonia: An Update on Guidelines Claudia Summa, BScPhm Pharmacy Resident September 12, 2006 Objectives To give a brief description of the pathophysiology of community acquired pneumonia

More information

Safety of an Out-Patient Intravenous Antibiotics Programme

Safety of an Out-Patient Intravenous Antibiotics Programme Safety of an Out-Patient Intravenous Antibiotics Programme Chan VL, Tang ESK, Leung WS, Wong L, Cheung PS, Chu CM Department of Medicine & Geriatrics United Christian Hospital Outpatient Parental Antimicrobial

More information

DATA COLLECTION SECTION BY FRONTLINE TEAM. Patient Identifier/ Medical Record number (for facility use only)

DATA COLLECTION SECTION BY FRONTLINE TEAM. Patient Identifier/ Medical Record number (for facility use only) Assessment of Appropriateness of ICU Antibiotics (Patient Level Sheet) **Note this is intended for internal purposes only. Please do not return to PQC.** For this assessment, inappropriate antibiotic use

More information

Initial Antibiotic Selection and Patient Outcomes: Observations from the National Pneumonia Project

Initial Antibiotic Selection and Patient Outcomes: Observations from the National Pneumonia Project SUPPLEMENT ARTICLE Initial Antibiotic Selection and Patient Outcomes: Observations from the National Pneumonia Project Dale W. Bratzler, Allen Ma, and Wato Nsa Oklahoma Foundation for Medical Quality,

More information

Study of Fluoroquinolone Usage Sensitivity and Resistance Patterns

Study of Fluoroquinolone Usage Sensitivity and Resistance Patterns Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2013, 5 (5):195-199 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4

More information

CLINICAL PROTOCOL FOR COMMUNITY ACQUIRED PNEUMONIA. SCOPE: Western Australia. CORB score equal or above 1. All criteria must be met:

CLINICAL PROTOCOL FOR COMMUNITY ACQUIRED PNEUMONIA. SCOPE: Western Australia. CORB score equal or above 1. All criteria must be met: CLINICAL PROTOCOL F COMMUNITY ACQUIRED PNEUMONIA SCOPE: Western Australia All criteria must be met: Inclusion Criteria Exclusion Criteria CB score equal or above 1. Mild/moderate pneumonia confirmed by

More information

Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)

Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Pneumonia Community Acquired Pneumonia 1) Is it pneumonia? ie new symptoms and signs of

More information

Measure Information Form

Measure Information Form Release Notes: Measure Information Form Version 2.0 **NQF-ENDORSED VOUNTRY CONSENSUS STNDRDS FOR HOSPIT CRE** Measure Information Form Measure Set: Surgical Care Improvement Project (SCIP) Set Measure

More information

Impact of Blood Cultures on the Changes of Treatment in Hospitalized Patients with Community-Acquired Pneumonia

Impact of Blood Cultures on the Changes of Treatment in Hospitalized Patients with Community-Acquired Pneumonia Send Orders of Reprints at reprints@benthamscience.net 60 The Open Respiratory Medicine Journal, 2013, 7, 60-66 Impact of Blood Cultures on the Changes of Treatment in Hospitalized Patients with Community-Acquired

More information

Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)

Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Community Acquired 1) Is it pneumonia? ie new symptoms and signs of a lower respiratory

More information

Antimicrobial Stewardship

Antimicrobial Stewardship Antimicrobial Stewardship Report: 11 th August 2016 Issue: As part of ensuring compliance with the National Safety and Quality Health Service Standards (NSQHS), Yea & District Memorial Hospital is required

More information

Pneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center

Pneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center Pneumonia considerations 2017 Galia Rahav Infectious diseases unit Sheba medical center Sir William Osler (1849 1919) "Father of modern medicine Pneumonia: The old man's friend The captain of the men of

More information

Volume. December Infection. Notes. length of. cases as 90% 1 week. tonsillitis. First Line. sore throat / daily for 5 days. quinsy >4000.

Volume. December Infection. Notes. length of. cases as 90% 1 week. tonsillitis. First Line. sore throat / daily for 5 days. quinsy >4000. Volume 8; Number 22 LINCOLNSHIRE GUIDELINES FOR THE TREATMENT OF COMMONLYY OCCURRING INFECTIONS IN PRIMARY CARE: WINTER 2014/15 In this issue of the PACE Bulletin we present an update of our Guidelines

More information

JOINT CONFERENCE COMMITTEE CORE MEASURE UPDATE APRIL 13, 2010

JOINT CONFERENCE COMMITTEE CORE MEASURE UPDATE APRIL 13, 2010 JOINT CONFERENCE COMMITTEE CORE MEASURE UPDATE APRIL 13, 2010 See attached Core Measure Performance Graphs Data through Quarter 4 2009. Core Measure Performance is reported publicly at: WWW.HOSPITALCOMPARE.HHS.GOV

More information

ORIGINAL INVESTIGATION. Doxycycline Is a Cost-effective Therapy for Hospitalized Patients With Community-Acquired Pneumonia

ORIGINAL INVESTIGATION. Doxycycline Is a Cost-effective Therapy for Hospitalized Patients With Community-Acquired Pneumonia ORIGINAL INVESTIGATION Doxycycline Is a Cost-effective Therapy for Hospitalized Patients With Community-Acquired Pneumonia Reba K. Ailani, MD; Gautami Agastya, MD; Rajesh K. Ailani, MD; Beejadi N. Mukunda,

More information

Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance

Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance Journal of Antimicrobial Chemotherapy (2008) 61, 1162 1168 doi:10.1093/jac/dkn073 Advance Access publication 29 February 2008 Treatment costs associated with community-acquired pneumonia by community level

More information

Thorax Online First, published on August 23, 2009 as /thx

Thorax Online First, published on August 23, 2009 as /thx Thorax Online First, published on August 23, 2009 as 10.1136/thx.2009.118588 PROSPECTIVE, RANDOMIZED STUDY TO COMPARE EMPIRICAL TREATMENT VERSUS TARGETED TREATMENT ON THE BASIS OF THE URINE ANTIGEN RESULTS

More information

Challenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S.

Challenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S. Challenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S. Overview of benchmarking Antibiotic Use Scott Fridkin, MD, Senior Advisor for Antimicrobial

More information

Antibiotic usage in nosocomial infections in hospitals. Dr. Birgit Ross Hospital Hygiene University Hospital Essen

Antibiotic usage in nosocomial infections in hospitals. Dr. Birgit Ross Hospital Hygiene University Hospital Essen Antibiotic usage in nosocomial infections in hospitals Dr. Birgit Ross Hospital Hygiene University Hospital Essen Infection control in healthcare settings - Isolation - Hand Hygiene - Environmental Hygiene

More information

M Falguera, 1 A Ruiz-González, 1 J A Schoenenberger, 2 C Touzón, 1 IGázquez, 1 C Galindo, 1 J M Porcel 1. Respiratory infection

M Falguera, 1 A Ruiz-González, 1 J A Schoenenberger, 2 C Touzón, 1 IGázquez, 1 C Galindo, 1 J M Porcel 1. Respiratory infection See Editorial, p93 1 Internal Medicine Service, Hospital Universitari Arnau de Vilanova, Universitat de Lleida, Institut de Recerca Biomèdia de Lleida (IRBLLEIDA), Lleida, Ciber de Enfermedades Respiratorias,

More information

Antimicrobial Stewardship:

Antimicrobial Stewardship: Antimicrobial Stewardship: Inpatient and Outpatient Elements Angela Perhac, PharmD afperhac@carilionclinic.org Disclosure I have no relevant finances to disclose. Objectives Review the core elements of

More information

Barriers to Intravenous Penicillin Use for Treatment of Nonmeningitis

Barriers to Intravenous Penicillin Use for Treatment of Nonmeningitis JCM Accepts, published online ahead of print on 7 July 2010 J. Clin. Microbiol. doi:10.1128/jcm.01012-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

Aspiration Pneumonia among Older Adults

Aspiration Pneumonia among Older Adults Lung Disease among Older Adults R.A. Harrison, MD, FRCPC, Department of Internal Medicine and Division of Infectious Diseases, University of Alberta, Edmonton, AB. T.J. Marrie, MD, FRCPC, Department of

More information

SHC Clinical Pathway: HAP/VAP Flowchart

SHC Clinical Pathway: HAP/VAP Flowchart SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal

More information

More than 4 million episodes of communityacquired

More than 4 million episodes of communityacquired Overview of Recent Guidelines for the Management of Community-Acquired Pneumonia David C. Rhew, MD More than 4 million episodes of communityacquired pneumonia (CAP) occur each year in the United States,

More information

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012 Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton

More information

Healthcare-associated Infections and Antimicrobial Use Prevalence Survey

Healthcare-associated Infections and Antimicrobial Use Prevalence Survey Healthcare-associated Infections and Antimicrobial Use Prevalence Survey Shamima Sharmin, M.B.B.S., MSc, MPH Emerging Infections Program New Mexico Department of Health Agenda Recognize healthcare-associated

More information

Stewardship: Challenges & Opportunities in the Gulf Region

Stewardship: Challenges & Opportunities in the Gulf Region Stewardship: Challenges & Opportunities in the Gulf Region Mushira Enani, MBBS, FRCPE, FACP,CIC Head- Infectious Disease Section King Fahad Medical City Outline Background of Healthcare system in GCC GCC

More information

Healthcare-Associated Pneumonia in the Emergency Department

Healthcare-Associated Pneumonia in the Emergency Department Healthcare-Associated Pneumonia in the Emergency Department Ellen M. Slaven, M.D., 1 Jairo I. Santanilla, M.D., 1,2 and Peter M. DeBlieux, M.D. 1 ABSTRACT Emergency medicine clinicians frequently diagnose

More information

Acute Pyelonephritis POAC Guideline

Acute Pyelonephritis POAC Guideline Acute Pyelonephritis POAC Guideline Refer full regional pathway http://aucklandregion.healthpathways.org.nz/33444 EXCLUSION CRITERIA: COMPLICATED PYELONEPHRITIS Discuss with relevant specialist for advice

More information

Combination vs Monotherapy for Gram Negative Septic Shock

Combination vs Monotherapy for Gram Negative Septic Shock Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham

More information

Research & Reviews: Journal of Hospital and Clinical Pharmacy

Research & Reviews: Journal of Hospital and Clinical Pharmacy Research & Reviews: Journal of Hospital and Clinical Pharmacy Empiric Antibiotic Prescribing For Community Acquired Pneumonia and Patient Characteristics Associated with Broad Spectrum Antibiotic Use Mirza

More information

Antimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS

Antimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS Antimicrobial Stewardship in the Long Term Care and Outpatient Settings Carlos Reyes Sacin, MD, AAHIVS Disclosure Speaker and consultant in HIV medicine for Gilead and Jansen Pharmaceuticals Objectives

More information

TREAT Steward. Antimicrobial Stewardship software with personalized decision support

TREAT Steward. Antimicrobial Stewardship software with personalized decision support TREAT Steward TM Antimicrobial Stewardship software with personalized decision support ANTIMICROBIAL STEWARDSHIP - Interdisciplinary actions to improve patient care Quality Assurance The aim of antimicrobial

More information

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017. Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing

More information

Objectives 4/26/2017. Co-Investigators Sadie Giuliani, PharmD, BCPS Claude Tonnerre, MD Jayme Hartzell, PharmD, MS, BCPS

Objectives 4/26/2017. Co-Investigators Sadie Giuliani, PharmD, BCPS Claude Tonnerre, MD Jayme Hartzell, PharmD, MS, BCPS IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,

More information

ORIGINAL INVESTIGATION. Causes and Factors Associated With Early Failure in Hospitalized Patients With Community-Acquired Pneumonia

ORIGINAL INVESTIGATION. Causes and Factors Associated With Early Failure in Hospitalized Patients With Community-Acquired Pneumonia ORIGINAL INVESTIGATION Causes and Factors Associated With Failure in Hospitalized Patients With Community-Acquired Pneumonia Beatriz Rosón, MD; Jordi Carratalà, MD; Núria Fernández-Sabé, MD; Fe Tubau,

More information

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA

More information

Suitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP)

Suitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP) STUDY PROTOCOL Suitability of Antibiotic Treatment for CAP (CAPTIME) Purpose The duration of antibiotic treatment in community acquired pneumonia (CAP) lasts about 9 10 days, and is determined empirically.

More information

Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship

Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship Natalie R. Tucker, PharmD Antimicrobial Stewardship Pharmacist Tyson E. Dietrich, PharmD PGY2 Infectious Diseases

More information

Final published version:

Final published version: Influence of Antibiotics on the Detection of Bacteria by Culture-Based and Culture-Independent Diagnostic Tests in Patients Hospitalized With Community-Acquired Pneumonia. Aaron Harris, Emory University

More information

Antimicrobial stewardship in managing septic patients

Antimicrobial stewardship in managing septic patients Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest

More information

The Core Elements of Antibiotic Stewardship for Nursing Homes

The Core Elements of Antibiotic Stewardship for Nursing Homes The Core Elements of Antibiotic Stewardship for Nursing Homes APPENDIX B: Measures of Antibiotic Prescribing, Use and Outcomes National Center for Emerging and Zoonotic Infectious Diseases Division of

More information

NHSN 2015 Rebaseline and TDH Updates. Ashley Fell, MPH

NHSN 2015 Rebaseline and TDH Updates. Ashley Fell, MPH NHSN 2015 Rebaseline and TDH Updates Ashley Fell, MPH Standardized Infection Ratio (SIR) SIR = Observed O HAIs Predicted P HAIs 2 National Baseline Years 2015 (New) NHSN Baseline All HAI Types: CLABSI,

More information

Curricular Components for Infectious Diseases EPA

Curricular Components for Infectious Diseases EPA Curricular Components for Infectious Diseases EPA 1. EPA Title Promoting antimicrobial stewardship based on microbiological principles 2. Description of the A key role for subspecialists is to utilize

More information

Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases

Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses

More information

TITLE: Recognition and Diagnosis of Sepsis in Rural or Remote Areas: A Review of Clinical and Cost-Effectiveness and Guidelines

TITLE: Recognition and Diagnosis of Sepsis in Rural or Remote Areas: A Review of Clinical and Cost-Effectiveness and Guidelines TITLE: Recognition and Diagnosis of Sepsis in Rural or Remote Areas: A Review of Clinical and Cost-Effectiveness and Guidelines DATE: 11 August 2016 CONTEXT AND POLICY ISSUES Sepsis, defined in the 2016

More information

DOES TIMING OF ANTIBIOTICS IMPACT OUTCOME IN SEPSIS? Saravana Kumar MD HEAD,DEPT OF EM,DR MEHTA S HOSPITALS CHENNAI,INDIA

DOES TIMING OF ANTIBIOTICS IMPACT OUTCOME IN SEPSIS? Saravana Kumar MD HEAD,DEPT OF EM,DR MEHTA S HOSPITALS CHENNAI,INDIA DOES TIMING OF ANTIBIOTICS IMPACT OUTCOME IN SEPSIS? Saravana Kumar MD HEAD,DEPT OF EM,DR MEHTA S HOSPITALS CHENNAI,INDIA drsaravanakumar.ep@gmail.com JOINT SECRETARY RECOMMENDATIONS: INITIAL RESUSCITATION

More information

Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days

Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of

More information

Received: Accepted: Access this article online Website: Quick Response Code:

Received: Accepted: Access this article online Website:   Quick Response Code: Indian Journal of Drugs, 2016, 4(3), 69-74 ISSN: 2348-1684 STUDY ON UTILIZATION PATTERN OF ANTIBIOTICS AT A PRIVATE CORPORATE HOSPITAL B. Chitra Department of Pharmacy Practice, College of Pharmacy, Sri

More information

SECTION 3A. Section 3A Criteria for Optional Special Authorization of Select Drug Products

SECTION 3A. Section 3A Criteria for Optional Special Authorization of Select Drug Products SECTION 3A Criteria for Optional Special Authorization of Select Drug Products Section 3A Criteria for Optional Special Authorization of Select Drug Products CRITERIA FOR OPTIONAL SPECIAL AUTHORIZATION

More information

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial

More information

Telephone Clindamycin iv to oral conversion P.O. Box 189 Navan, ON, K4B 1J4 Canada. Sitemap

Telephone Clindamycin iv to oral conversion P.O. Box 189 Navan, ON, K4B 1J4 Canada. Sitemap Telephone 613-835-9490 Clindamycin iv to oral conversion P.O. Box 189 Navan, ON, K4B 1J4 Canada Sitemap 12-3-2018 Healthy people commonly aspirate small amounts of oral secretions, but normal defense mechanisms

More information

Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance Joshua P. Metlay 1 and Daniel E.

Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance Joshua P. Metlay 1 and Daniel E. Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance Joshua P. Metlay 1 and Daniel E. Singer 2 1 Veterans Affairs Medical Center and Division of General Internal

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:

More information

Epidemiology of early-onset bloodstream infection and implications for treatment

Epidemiology of early-onset bloodstream infection and implications for treatment Epidemiology of early-onset bloodstream infection and implications for treatment Richard S. Johannes, MD, MS Marlborough, Massachusetts Health care-associated infections: For over 35 years, infections

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

Adequacy of Early Empiric Antibiotic Treatment and Survival in Severe Sepsis: Experience from the MONARCS Trial

Adequacy of Early Empiric Antibiotic Treatment and Survival in Severe Sepsis: Experience from the MONARCS Trial BRIEF REPORT Adequacy of Early Empiric Antibiotic Treatment and Survival in Severe Sepsis: Experience from the MONARCS Trial Rodger D. MacArthur, 1 Mark Miller, 2 Timothy Albertson, 3 Edward Panacek, 3

More information

Antibiotic stewardship in long term care

Antibiotic stewardship in long term care Antibiotic stewardship in long term care Shira Doron, MD Associate Professor of Medicine Division of Geographic Medicine and Infectious Diseases Tufts Medical Center Boston, MA Consultant to Massachusetts

More information

Clinical Policy for the Management and Risk Stratification of Community-Acquired Pneumonia in Adults in the Emergency Department

Clinical Policy for the Management and Risk Stratification of Community-Acquired Pneumonia in Adults in the Emergency Department Clinical Policy for the Management and Risk Stratification of Community-Acquired Pneumonia in Adults in the Emergency Department This clinical policy was developed by the ACEP Clinical Policies Committee

More information

M5 MEQs 2016 Session 3: SOB 18/11/16

M5 MEQs 2016 Session 3: SOB 18/11/16 M5 MEQs 2016 Session 3: SOB 18/11/16 http://tinyurl.com/hn7qzt3 Question 1 Ms Tan is a 52 year old female with no past medical history. She comes to the emergency department presenting with a fever for

More information

Levofloxacin and moxifloxacin resistant Haemophilus influenzae in a patient with common variable immunodeficiency (CVID): a case report

Levofloxacin and moxifloxacin resistant Haemophilus influenzae in a patient with common variable immunodeficiency (CVID): a case report 46 Case Report Levofloxacin and moxifloxacin resistant Haemophilus influenzae in a patient with common variable immunodeficiency (CVID): a case report CT Hapuarachchi 1, GK Karunaratne 2, NR de Silva 3,

More information

Antimicrobial Stewardship: Stopping the Spread of Antibiotic Resistance

Antimicrobial Stewardship: Stopping the Spread of Antibiotic Resistance Antimicrobial Stewardship: Stopping the Spread of Antibiotic Resistance Natalie Weber, PharmD PGY2 Critical Care Pharmacy Resident September 22, 2016 The speaker has no actual or potential conflicts of

More information

CME/CE QUIZ CME/CE QUESTIONS. a) 20% b) 22% c) 34% d) 35% b) Susceptible and resistant strains of typical respiratory

CME/CE QUIZ CME/CE QUESTIONS. a) 20% b) 22% c) 34% d) 35% b) Susceptible and resistant strains of typical respiratory CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for

More information

Clinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid

Clinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: HIM*, Medicaid Coding Implications Revision Log See Important Reminder at the end

More information

PNEUMONIA PRACTICE GUIDELINES

PNEUMONIA PRACTICE GUIDELINES PNEUMONIA PRACTICE GUIDELINES WHERE ARE WE NOW STEPHEN SOKALSKI DO FACOI ADVOCATE CHRIST MEDICAL CENTER PNEUMONIA GUIDELINES THEY SEEMED LIKE A GOOD IDEA AT THE TIME. ARE THEY STILL? INDICATORS INCLUDED

More information

Timing of antibiotic administration and outcomes of hospitalized patients with community-acquired and healthcare-associated pneumonia

Timing of antibiotic administration and outcomes of hospitalized patients with community-acquired and healthcare-associated pneumonia ORIGINAL ARTICLE INFECTIOUS DISEASES Timing of antibiotic administration and outcomes of hospitalized patients with community-acquired and healthcare-associated pneumonia A. Simonetti 1, D. Viasus 1, C.

More information

Antibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco

Antibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance

More information

Gastric Dilatation-Volvulus

Gastric Dilatation-Volvulus Gastric Dilatation-Volvulus The term "ACVS Diplomate" refers to a veterinarian who has been board certified in veterinary surgery. Only veterinarians who have successfully completed the certification requirements

More information

MAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges

MAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control

More information

Antimicrobial stewardship: Quick, don t just do something! Stand there!

Antimicrobial stewardship: Quick, don t just do something! Stand there! Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger

More information

MDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta

MDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental

More information

Clinical Guideline. District Infectious Diseases Management. Go to Guideline. District Infectious Diseases Management CG 18_24

Clinical Guideline. District Infectious Diseases Management. Go to Guideline. District Infectious Diseases Management CG 18_24 Clinical Guideline District Infectious Diseases Management Sites where Clinical Guideline applies All facilities This Clinical Guideline applies to: 1. Adults Yes 2. Children up to 16 years Yes 3. Neonates

More information

Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version

Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control

More information